ATE270111T1 - Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren - Google Patents

Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren

Info

Publication number
ATE270111T1
ATE270111T1 AT94911691T AT94911691T ATE270111T1 AT E270111 T1 ATE270111 T1 AT E270111T1 AT 94911691 T AT94911691 T AT 94911691T AT 94911691 T AT94911691 T AT 94911691T AT E270111 T1 ATE270111 T1 AT E270111T1
Authority
AT
Austria
Prior art keywords
biologically
composition
toxicity
reducing
biologically active
Prior art date
Application number
AT94911691T
Other languages
English (en)
Inventor
Lawrence Tamarkin
Giulio Franco Paciotti
Original Assignee
Cytimmune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytimmune Sciences Inc filed Critical Cytimmune Sciences Inc
Application granted granted Critical
Publication of ATE270111T1 publication Critical patent/ATE270111T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94911691T 1993-03-18 1994-03-18 Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren ATE270111T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3338593A 1993-03-18 1993-03-18
PCT/US1994/003177 WO1994021288A1 (en) 1993-03-18 1994-03-18 Composition and method for reducing toxicity of biologically-active factors

Publications (1)

Publication Number Publication Date
ATE270111T1 true ATE270111T1 (de) 2004-07-15

Family

ID=21870121

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911691T ATE270111T1 (de) 1993-03-18 1994-03-18 Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren

Country Status (7)

Country Link
EP (1) EP0690722B1 (de)
JP (1) JP3880063B2 (de)
AT (1) ATE270111T1 (de)
AU (1) AU6414994A (de)
CA (1) CA2158475C (de)
DE (1) DE69433870T2 (de)
WO (1) WO1994021288A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
NZ504292A (en) * 1997-11-10 2003-03-28 Cytimmune Sciences Inc Methods and compositions for enhancing immune response using a targeted delivery system and for the production of in vitro mabs
CA2309604C (en) * 1997-11-10 2010-01-12 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
AU2003231660B2 (en) * 1997-11-10 2006-05-18 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
CA2361377C (en) 1999-02-05 2009-02-03 Alk-Abello A/S Novel mucosal delivery system
FR2792639B1 (fr) 1999-04-26 2003-06-06 Neovacs Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
DK2116257T3 (da) 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
JP5175020B2 (ja) * 2001-04-30 2013-04-03 サイティミューン サイエンシーズ， インコーポレイテッド コロイド状金属組成物および方法
CA2447614C (en) 2001-05-25 2009-08-11 Gorm Danscher A method of implanting heavy metal such as nobel metal, e.g. gold, and metal for use in implantation
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10235602B4 (de) * 2002-08-02 2010-01-14 Universität Duisburg-Essen Metallcluster-Nanoverbindungen zur Behandlung von Tumorerkrankungen
ES2313031T3 (es) * 2003-06-20 2009-03-01 JOHNSON & JOHNSON MEDICAL LTD. Antimicrobianos que comprenden plata.
KR20060036476A (ko) 2003-08-08 2006-04-28 가부시키가이샤 티슈 타겟팅 쟈판 뇌 이동 활성을 가지는 폴리펩티드 및 그 이용
CA2548179A1 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
EP1782796A1 (de) * 2004-08-06 2007-05-09 Tissue Targeting Japan Inc. Träger zur migration in zerebralneuron mit metallkolloidteilchen
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
GB0500898D0 (en) * 2005-01-18 2005-02-23 Smith & Nephew Gold-protein coagulation
AU2007227256B2 (en) 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2219458B1 (de) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Zusammensetzungen und verfahren für die erzeugung von antikörpern
MX2010012437A (es) 2008-05-14 2011-06-01 Agriculture Victoria Serv Pty Uso de angiogenina o agonistas de angiogenina para tratar enfermedades y trastornos.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
AU2016305473B2 (en) * 2015-08-13 2021-08-19 Dana-Farber Cancer Institute, Inc. Biomaterials for combined radiotherapy and immunotherapy of cancer
JP6635319B1 (ja) * 2018-07-31 2020-01-22 株式会社東洋厚生製薬所 ナチュラルキラー細胞活性化剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269912A (en) * 1963-04-08 1966-08-30 Boehringer & Soehne Gmbh Aluminum oxide depot vaccines
FR2334366A2 (fr) * 1975-12-10 1977-07-08 Anvar Application a titre d'agents antiviraux de composes d'heteropolyanions contenant du tungstene combine a de l'antimoine
JPS62162963A (ja) * 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
DE69027121T3 (de) * 1989-08-07 2001-08-30 Peptech Ltd Bindeligande für tumornekrosisfaktor

Also Published As

Publication number Publication date
DE69433870D1 (de) 2004-08-05
EP0690722A4 (de) 1997-08-06
EP0690722B1 (de) 2004-06-30
DE69433870T2 (de) 2005-06-30
CA2158475C (en) 2009-06-02
AU6414994A (en) 1994-10-11
JPH08511236A (ja) 1996-11-26
JP3880063B2 (ja) 2007-02-14
EP0690722A1 (de) 1996-01-10
CA2158475A1 (en) 1994-09-29
WO1994021288A1 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
ATE270111T1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
ATE219674T1 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
NZ251320A (en) Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
ATE81011T1 (de) Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
DK127788A (da) Farmaceutiske praeparater til anvendelse til behandling eller forebyggelse af sygdomme i mavetarmkanalen
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ATE218868T1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
DE69902520T2 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
ATE62789T1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE69719095D1 (de) Gallensauersälze mit physiologisch aktiven metalle und ihre verwendung zur therapeutischen behandlung
HUP0101602A2 (hu) Termékenységet javító készítmény, és annak alkalmazása
ATE175349T1 (de) Verwendung von etofibrat und pharmazeutische zusammensetzungen, enthaltend etofibrat, zur behandlung der diabetischen angio- und retinopathie
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
UA10825A (uk) Протимікробhий засіб
NO911470D0 (no) Sammensetning og behandling med biologisk aktive peptiderog visse anioner.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0690722

Country of ref document: EP